Key result
A mediation analysis of the SELECT trial could not fully ascribe the reduction in major cardiovascular events with semaglutide to known risk factors, with joint mediation estimated at 31.4%.
Why the study?
The mechanisms by which semaglutide reduces major adverse cardiovascular events in adults with pre-existing cardiovascular disease and elevated BMI without diabetes are not fully understood.
Does semaglutide reduce MACE through changes in body weight, waist circumference, hsCRP, HbA1c, lipids, blood pressure, eGFR, and UACR in adults with pre-existing CVD and BMI ≥27 kg/m2 without diabetes?
RCT
Placebo-controlled
Randomized
Does semaglutide reduce MACE through changes in body weight, waist circumference, hsCRP, HbA1c, lipids, blood pressure, eGFR, and UACR in adults with pre-existing CVD and BMI ≥27 kg/m2 without diabetes?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Our analyses could not fully ascribe the effects of semaglutide on cardiovascular disease to known risk factors with any certainty. Whether we combine all risk factors together or look at some subsets of the risk factors, no more than half of the reduction in heart disease could be explained by the changes in these risk factors. These results suggest that semaglutide should be considered a cardiovascular disease reduction drug and not just a weight loss drug.”
“The conclusion of this paper is appropriately humble. Known risk factor changes could not, with any confidence, explain all of the GLP-1RA effects on major adverse cardiovascular events.”
“By all accounts, the remarkable story of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in cardiovascular medicine has been one of serendipity. Two years ago, in the European Heart Journal, we wrote that the journey of semaglutide was one such story—a drug born to lower glucose that has become the most versatile weapon against cardiometabolic-, kidney- and obesity-related diseases”
The cardiovascular benefits of semaglutide in the SELECT trial cannot be fully explained by changes in known risk factors such as body weight, waist circumference, or hsCRP, suggesting additional mechanisms of cardiovascular protection.
BACKGROUND AND AIMS: In SELECT, subcutaneous semaglutide (target dose 2.4 mg) weekly in adults with pre-existing cardiovascular disease and body mass index ≥27 kg/m2 without diabetes significantly reduced major adverse cardiovascular events (MACE) by 20% vs placebo. This analysis explored potential mediators of this cardiovascular benefit. METHODS: Changes from randomization to 24 months in body weight, waist circumference, plasma high-sensitivity C-reactive protein (hsCRP), glycated haemoglobin (HbA1c), lipids, blood pressure, estimated glomerular filtration rate, and urinary albumin-to-creatinine ratio were examined individually, and in combination, as potential mediators of MACE risk reduction, using the Vansteelandt repeated regression method (a counterfactual approach). RESULTS: Semaglutide significantly (P < .05) improved all potential mediators investigated. Point estimates for % mediation were largest for waist circumference (64.0% [95% confidence interval (CI) 27.5, 179.6]), hsCRP (42.1% [17.9, 110.5]), HbA1c (29.0% [-20.7, 120.5]), and body weight (19.5% [-33.0, 110.7]), examined separately, but all had wide CIs. Supplementary analyses suggested unreliability of estimates for body weight and waist circumference, potentially due to differing relationship of body weight and waist change to MACE between treatment arms. Multivariable analysis estimated joint mediation for all potential mediators combined to be 31.4% (95% CI -30.1, 143.6). When variables other than body weight and waist circumference were considered, % mediation was 46.0% (95% CI -6.0, 161.0). CONCLUSIONS: Mediation analyses could not fully ascribe the effects of semaglutide on MACE to known risk factors in SELECT with any certainty. Further investigation of potential additional biomarkers and mediators of semaglutide's cardiovascular protective effect are of interest.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
No takes yet. Share an insight, caveat, or question.
Colhoun et al. (2026) conducted an RCT in Pre-existing cardiovascular disease and overweight/obesity without diabetes. Semaglutide vs. Placebo was evaluated on Joint mediation for all potential mediators combined for MACE risk reduction (31.4% mediation, 95% CI -30.1, 143.6). A mediation analysis of the SELECT trial could not fully ascribe the reduction in major cardiovascular events with semaglutide to known risk factors, with joint mediation estimated at 31.4%.
Synapse has enriched 10 related papers. Consider them for comparative context: